Ergomed has released a trading update announcing strong revenue growth in 2022 of 23% plus similar growth in its order book, providing visibility on 2023. The business continues to execute well with 2022 EBITDA in line with forecasts. The balance sheet is net cash, providing optionality on acquisition growth.
Davy research
Davy ResearchMarket comment - Irish consumer spending holding up better than expected
Davy ResearchDisruptive technology - Week 3 – US Bellwether Blast: MSFT’s Q223 earnings
Davy ResearchPaper & packaging - Weak box demand, but cost tailwind and resilient pricing
Davy ResearchRyanair Holdings - Delivers in line with January 4th statement
Davy ResearchTreatt plc - AGM trading update
Davy ResearchMarket comment - Irish housing completions grow close to 30,000 in 2022
Davy ResearchGreencoat Renewables - 2022 performance confirms positive outlook
Davy ResearchEntain - BetMGM – 2023 guidance implies upside to revenue forecast